These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 9259023

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Competitive NMDA receptor antagonists disrupt prepulse inhibition without reduction of startle amplitude in a dopamine receptor-independent manner in mice.
    Furuya Y, Kagaya T, Ogura H, Nishizawa Y.
    Eur J Pharmacol; 1999 Jan 08; 364(2-3):133-40. PubMed ID: 9932715
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine.
    Bakshi VP, Geyer MA.
    J Neurosci; 1998 Oct 15; 18(20):8394-401. PubMed ID: 9763482
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit.
    Chaperon F, Müller W, Auberson YP, Tricklebank MD, Neijt HC.
    Behav Pharmacol; 2003 Sep 15; 14(5-6):477-87. PubMed ID: 14501261
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term effects of developmental PCP administration on sensorimotor gating in male and female rats.
    Rasmussen BA, O'Neil J, Manaye KF, Perry DC, Tizabi Y.
    Psychopharmacology (Berl); 2007 Jan 15; 190(1):43-9. PubMed ID: 17047931
    [Abstract] [Full Text] [Related]

  • 18. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity.
    Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A.
    Neuropharmacology; 2002 Dec 15; 43(8):1199-209. PubMed ID: 12527469
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. NMDA receptor antagonists acting at the glycineB site in rat models for antipsychotic-like activity.
    Karcz-Kubicha M, Wedzony K, Zajaczkowski W, Danysz W.
    J Neural Transm (Vienna); 1999 Dec 15; 106(11-12):1189-204. PubMed ID: 10651113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.